Rethinking When to Start Long-Acting HIV Therapy

Why It Matters

If long‑acting injectables can achieve suppression without prior oral control, clinicians gain a new tool for patients struggling with daily adherence, potentially improving outcomes and reducing transmission.

Key Takeaways

• 11% of OPERA patients started CAB+RPV LA with viral load >50 copies/mL
• Suppression rates approached those of already‑suppressed patients despite initial viremia
• Injectable regimen may bypass adherence barriers like stigma and pill fatigue
• Ongoing trials will define resistance risk and optimal patient selection

Pulse Analysis

Long‑acting HIV therapy has reshaped treatment paradigms by offering an alternative to daily oral regimens. Cabotegravir plus rilpivirine (CAB+RPV LA) received FDA approval for patients who have already achieved viral suppression, addressing adherence challenges that plague many on lifelong pill schedules. However, the real‑world OPERA cohort now suggests the injectable could be effective even when initiated during low‑level viremia, expanding its potential use beyond maintenance to a more proactive role in achieving suppression.

The OPERA analysis examined more than 5,000 individuals, finding that roughly one in nine started CAB+RPV LA with viral loads above the 50‑copy threshold. Despite this, a substantial proportion attained undetectable levels, with suppression trajectories mirroring those of patients who began the regimen already suppressed. This evidence counters the conventional wisdom that oral therapy must first control the virus before switching to injectables, hinting that early adoption of long‑acting agents might mitigate common barriers such as stigma, pill fatigue, and irregular clinic visits.

While promising, the data raise critical questions about resistance development, optimal timing, and patient selection criteria. Clinicians must weigh the risk of suboptimal drug exposure against the benefits of reduced dosing frequency. Ongoing phase‑III trials and pharmacokinetic studies aim to define safety margins and identify which subpopulations—such as those with adherence difficulties or limited healthcare access—stand to gain most. Should these investigations confirm the OPERA findings, treatment guidelines could shift, positioning long‑acting injectables as a frontline option rather than a last‑resort maintenance strategy, with significant implications for HIV care delivery and market dynamics.